Dimazon 50 mg/ml Solution for Injection

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: VMD (Veterinary Medicines Directorate)

Viambatanisho vya kazi:

Furosemide

Inapatikana kutoka:

MSD Animal Health UK Limited

ATC kanuni:

QC03CA01

INN (Jina la Kimataifa):

Furosemide

Dawa fomu:

Solution for injection

Dawa ya aina:

POM-V - Prescription Only Medicine – Veterinarian

Kundi la matibabu:

Cats, Cattle, Dogs, Horses

Eneo la matibabu:

Cardio Vascular diuretic

Idhini hali ya:

Authorized

Idhini ya tarehe:

2005-04-27

Tabia za bidhaa

Revised: December 2020
AN: 01394/2020
Page 1 of 6
SUMMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Dimazon 50 mg/ml solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Furosemide
50.0 mg
(as monoethanolamine salt)
EXCIPIENTS:
Benzyl alcohol
15.0 mg
Disodium edetate
1.0 mg
Sodium sulfite, anhydrous
1.8 mg
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
A clear, yellowish fluid.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, horses, cats and dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
A potent saluretic type of diuretic for parenteral administration to
cattle, horses,
cats and dogs. Dimazon is indicated in the treatment of oedemata
associated
with cardiac insufficiency, renal dysfunction, trauma and parasitic
disease. It is
also recommended for the treatment of mammary oedema and limb
oedemata.
The product gives rapid onset of diuretic action with increased sodium
and water
excretion. It is even effective where glomerular filtration is
impaired.
4.3
CONTRA-INDICATIONS
Do not use in cases of acute glomerular nephritis renal failure with
anuria,
electrolyte deficiency disease or overdosage with digitalis.
Do not use concurrently with aminoglycoside antibiotic treatment.
The therapeutic effect may be impaired by increased intake of drinking
water. So
Revised: December 2020
AN: 01394/2020
Page 2 of 6
far as the patient's condition allows, the amount of drinking water
should be
restricted.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Clinical experience with dogs indicates that improved results can
frequently be
achieved by supplementary administration of corticosteroids.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
In pulmonary oedema of cardiac origin, combined therapy with cardiac
glycosides is
advisable. Only during prolonged treatment is it necessary